J Christian Virchow1, Vibeke Backer2, Frédéric de Blay3, Piotr Kuna4, Christian Ljørring5, Jesus L Prieto6, Hanne H Villesen5. 1. Department of Pneumology/Intensive Care Medicine, Zentrum für Innere Medizin, Klinik I, Universitätsklinikum Rostock, Germany. Electronic address: j.c.virchow@med.uni-rostock.de. 2. Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen University, Denmark. 3. Chest Diseases Department, University Hospital of Strasbourg, Federation of Translational Medicine of Strasbourg, Strasbourg University, Strasbourg, France. 4. Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Lodz, Poland. 5. Global Clinical Development, ALK, Bøge Allé 1, DK 2970 Hørsholm, Denmark. 6. Department of Medicine, University of Valencia, Valencia, Spain.
Abstract
BACKGROUND: Exacerbations are a key outcome in clinical research, providing patient-relevant information about symptomatic control, health state and disease progression. Generally considered as an episode of (sub)acute deterioration of respiratory symptoms, a precise, clinically useful definition is needed for use in clinical trials. AIM AND METHODS: Focussing on moderate exacerbations, this opinion piece reviews landmark trials and current guidelines to provide a practical definition of a moderate exacerbation. Specifically, we adapt the ATS/ERS consensus statement of terminology Reddel et al. (2009) [1] which provides a conceptual (or 'theoretical') definition for moderate exacerbations, to an operational (or 'practical') criterion suitable for use in clinical research. RESULTS: The proposed definition for a moderate exacerbation requires ≥1 of the following criteria combined with a change in treatment: a) nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights or an increase of ≥0.75 from baseline in daily symptom scores on 2 consecutive days; b) increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase: 4 puffs/day); c) ≥20% decrease in PEF from baseline on at least 2 consecutive mornings/evenings or ≥20% decrease in FEV1 from baseline and/or d) visit to the emergency room/trial site for asthma treatment not requiring systemic corticosteroids. CONCLUSION: A clinically and patient-relevant, operational definition of moderate exacerbations is needed. The proposed definition has been endorsed by the EMA Scientific Advice Working Party in 2011and needs to be trialled in forthcoming clinical studies.
BACKGROUND: Exacerbations are a key outcome in clinical research, providing patient-relevant information about symptomatic control, health state and disease progression. Generally considered as an episode of (sub)acute deterioration of respiratory symptoms, a precise, clinically useful definition is needed for use in clinical trials. AIM AND METHODS: Focussing on moderate exacerbations, this opinion piece reviews landmark trials and current guidelines to provide a practical definition of a moderate exacerbation. Specifically, we adapt the ATS/ERS consensus statement of terminology Reddel et al. (2009) [1] which provides a conceptual (or 'theoretical') definition for moderate exacerbations, to an operational (or 'practical') criterion suitable for use in clinical research. RESULTS: The proposed definition for a moderate exacerbation requires ≥1 of the following criteria combined with a change in treatment: a) nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights or an increase of ≥0.75 from baseline in daily symptom scores on 2 consecutive days; b) increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase: 4 puffs/day); c) ≥20% decrease in PEF from baseline on at least 2 consecutive mornings/evenings or ≥20% decrease in FEV1 from baseline and/or d) visit to the emergency room/trial site for asthma treatment not requiring systemic corticosteroids. CONCLUSION: A clinically and patient-relevant, operational definition of moderate exacerbations is needed. The proposed definition has been endorsed by the EMA Scientific Advice Working Party in 2011and needs to be trialled in forthcoming clinical studies.
Authors: Nicholas Nassikas; Keith Spangler; Neal Fann; Christopher G Nolte; Patrick Dolwick; Tanya L Spero; Perry Sheffield; Gregory A Wellenius Journal: Environ Res Date: 2020-01-31 Impact factor: 6.498
Authors: Alberto Papi; Dave Singh; J Christian Virchow; G Walter Canonica; Andrea Vele; George Georges Journal: Clin Transl Allergy Date: 2022-04-17 Impact factor: 5.657
Authors: Edward Kerwin; Steven Pascoe; Zelie Bailes; Robert Nathan; David Bernstein; Ronald Dahl; Robyn von Maltzahn; Kevin Robbins; Andrew Fowler; Laurie Lee Journal: Respir Res Date: 2020-06-12
Authors: Amelia Licari; Giorgio Ciprandi; Gian Luigi Marseglia; Michela Silvestri; Maria Angela Tosca; Elisa Anastasio; Ilaria Brambilla; Carlo Caffarelli; Riccardo Castagnoli; Loredana Chini; Riccardo Ciprandi; Valentina De Vittori; Marzia Duse; Maria Elisa Di Cicco; Luciana Indinnimeo; Ahmad Kantar; Maddalena Leone; Guido Marinelli; Viviana Moschese; Roberta Olcese; Diego G Peroni; Angela Pistorio; Claudia Salmaso; Anna Maria Zicari Journal: Acta Biomed Date: 2020-09-15